about
Hepatitis E virus: do locally acquired infections in Australia necessitate laboratory testing in acute hepatitis patients with no overseas travel history?Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative surveyEmerging infectious disease agents and blood safety in Australia: spotlight on Zika virus.Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk.Antibodies to Leptospira among blood donors in higher-risk areas of Australia: possible implications for transfusion safetySeroprevalence of Antibodies to Ross River and Barmah Forest Viruses: Possible Implications for Blood Transfusion Safety After Extreme Weather Events.Emerging viral threats to the Australian blood supply.Hepatitis E virus infections in travellers: assessing the threat to the Australian blood supply.No evidence of a significantly increased risk of transfusion-transmitted human immunodeficiency virus infection in Australia subsequent to implementing a 12-month deferral for men who have had sex with men.The current status and potential role of laboratory testing to prevent transfusion-transmitted malaria.Hepatitis E virus seroepidemiology: a post-earthquake study among blood donors in Nepal.Implications of dengue outbreaks for blood supply, Australia.A Comparative Study of Assay Performance of Commercial Hepatitis E Virus Enzyme-Linked Immunosorbent Assay Kits in Australian Blood Donor Samples.Mitigating the Risk of Transfusion-Transmitted Dengue in Australia.Can blood tranfusion transmit cancer? A literature review.Surveillance of transfusion-transmissible infections comparison of systems in five developed countries.The Epidemiology of Imported Malaria and Transfusion Policy in 5 Nonendemic Countries.Hepatitis E virus RNA in Australian blood donors: prevalence and risk assessment.Refining the risk estimate for transfusion-transmission of occult hepatitis B virus.Detection of emergent strains of West Nile virus with a blood screening assay.Blood safety implications of donors using HIV pre-exposure prophylaxis.Duration of Ross River viraemia in a mouse model--implications for transfusion transmission.Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus.The risk of dengue transmission by blood during a 2004 outbreak in Cairns, Australia.Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region.Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT.Re-evaluating the residual risk of transfusion-transmitted Ross River virus infection.The residual risk of transfusion-transmitted cytomegalovirus infection associated with leucodepleted blood components.First reported case of transfusion-transmitted Ross River virus infection.Infectivity of blood components from donors with occult hepatitis B infection - results from an Australian lookback programme.Reconsideration of blood donation testing strategy for human T-cell lymphotropic virus in Australia.Hepatitis B virus nucleic acid amplification testing of Australian blood donors highlights the complexity of confirming occult hepatitis B virus infection.A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening.Hepatitis E virus and implications for blood supply safety, Australia.Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003.Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.Comparison of two automated nucleic acid testing systems for simultaneous detection of human immunodeficiency virus and hepatitis C virus RNA and hepatitis B virus DNA.The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia.Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies.Emerging infectious disease outbreaks: estimating disease risk in Australian blood donors travelling overseas.
P50
Q27011308-5EFF622C-767E-4503-84E1-9D585EA537FCQ27487786-6257AFFE-B684-4137-A98A-4122CB152819Q30145544-027400B2-6581-4344-85E0-F7D2CBC316F6Q30145555-9373EC46-5752-456B-938B-828460E4AC77Q30833120-66D75821-4D93-46AE-8687-FF6CD93424EFQ30881753-E897A942-6458-48C8-9111-7393A0A7BAC8Q33368262-3B4FC0B6-F7A7-4713-87A9-B5C3547600CFQ33739483-12E345EB-F6B4-4C55-BC94-6694D18FA2F1Q34128173-001D54B3-8111-40C7-8759-FD9C477DBAE6Q36190649-ACBE4D88-651E-49A7-B27D-35DF1CD14962Q36204155-3F3AF5AD-FBA7-4260-9BB6-63F6CC0149A2Q36825504-7BED51DA-B64E-4345-B57C-05358575F21AQ37424582-56F5C7DB-3C10-4E53-9C3F-46296CA30F62Q37443189-17D3CE7C-1B4E-43E5-83E7-07FA94FDF851Q37775323-065D8B2D-5767-4186-904D-01AAEC20D449Q37938206-5554B40A-066D-4349-8193-85BF08AC1F4FQ38453746-B9B37D6A-0555-4B10-995D-B987C0E48355Q38612287-69BF5A16-E558-4EE9-9A6A-23C833E7BE5BQ39450759-B9C922A6-73B0-4AE9-A946-CCCD7176CA2BQ40127918-C82F03B9-289E-42CC-B36F-EB9A51A4151BQ40261341-61F7E71D-D0EA-4E94-A86E-95A7B3DFA52CQ40311855-91EF4AB4-AFE1-416A-ACEB-7F7C4DF40968Q40383406-3CA71030-E891-412C-86E4-60F9B891D0B2Q40391653-37531C9D-A897-40B4-8306-D87C08B8B4F9Q40513893-ED8DFDA0-749C-46AB-8D80-A66F1CA8A0E7Q40622701-C674989C-FDCD-4DCE-8595-FF6BAB1F56D7Q40839225-B65393D1-FE83-4785-BF19-BD41DCEE9909Q41100504-6C673CD3-437C-4AE7-94FD-985852689F23Q41439203-9D12C792-25C4-4DFD-BA4A-9B594EF56FD6Q41734031-E6E67582-8861-4D71-ACBD-41EABCD6E049Q41928215-79A70CEF-55C1-4F70-8C3C-AF59D968301CQ42230165-8771EC0D-9172-4894-9C01-CED0F0D42F34Q42257442-B715AFB1-66E6-4EEF-B326-35807EE022C2Q42968684-1D764144-242A-43D8-933E-3E8150D8A449Q42992279-06F5DB71-893B-42E4-921C-6CBC4B76DE63Q43036225-F4377CC2-1760-4D7F-8067-3A00B2865620Q43040836-2E7C881C-3DA7-4CD9-8B57-420F16AB8C04Q43041881-740ACA26-3ACB-4E4A-A195-A0025FCEEDC2Q43041997-963C48C9-123F-45F4-8A30-526DB7DAAEB4Q43047264-024F00E4-E4C1-4781-B7FE-85CC650D79B7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Clive R. Seed
@ast
Clive R. Seed
@en
Clive R. Seed
@es
Clive R. Seed
@nl
Clive R. Seed
@sl
type
label
Clive R. Seed
@ast
Clive R. Seed
@en
Clive R. Seed
@es
Clive R. Seed
@nl
Clive R. Seed
@sl
prefLabel
Clive R. Seed
@ast
Clive R. Seed
@en
Clive R. Seed
@es
Clive R. Seed
@nl
Clive R. Seed
@sl
P106
P1153
6602359324
P21
P31
P496
0000-0002-0234-4507